Compare LILA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILA | TWST |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | LILA | TWST |
|---|---|---|
| Price | $7.83 | $46.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $9.75 | ★ $47.89 |
| AVG Volume (30 Days) | 444.3K | ★ 1.4M |
| Earning Date | 02-18-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $391,557,000.00 |
| Revenue This Year | $1.37 | $16.77 |
| Revenue Next Year | N/A | $15.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.59 |
| 52 Week Low | $4.26 | $23.30 |
| 52 Week High | $9.04 | $54.74 |
| Indicator | LILA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 69.16 |
| Support Level | $7.26 | $39.66 |
| Resistance Level | $7.95 | $43.34 |
| Average True Range (ATR) | 0.27 | 2.50 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 85.06 | 77.41 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.